scholarly journals Increasing the Power of Polyphenols through Nanoencapsulation for Adjuvant Therapy against Cardiovascular Diseases

Molecules ◽  
2021 ◽  
Vol 26 (15) ◽  
pp. 4621
Author(s):  
Lucileno Rodrigues Trindade ◽  
Davi Vieira Teixeira da da Silva ◽  
Diego dos Santos Baião ◽  
Vania Margaret Flosi Paschoalin
Keyword(s):  
Clinical Trials ◽  
Cardiovascular Diseases ◽  
Adjuvant Therapy ◽  
Vascular Diseases ◽  
Ppar Γ ◽  
Epidemiological Surveys ◽  
Genes Encoding ◽  
And Oxidative Stress ◽  
Gradual Release ◽  
Inflammatory Action

Polyphenols play a therapeutic role in vascular diseases, acting in inherent illness-associate conditions such as inflammation, diabetes, dyslipidemia, hypertension, and oxidative stress, as demonstrated by clinical trials and epidemiological surveys. The main polyphenol cardioprotective mechanisms rely on increased nitric oxide, decreased asymmetric dimethylarginine levels, upregulation of genes encoding antioxidant enzymes via the Nrf2-ARE pathway and anti-inflammatory action through the redox-sensitive transcription factor NF-κB and PPAR-γ receptor. However, poor polyphenol bioavailability and extensive metabolization restrict their applicability. Polyphenols carried by nanoparticles circumvent these limitations providing controlled release and better solubility, chemical protection, and target achievement. Nano-encapsulate polyphenols loaded in food grade polymers and lipids appear to be safe, gaining resistance in the enteric route for intestinal absorption, in which the mucoadhesiveness ensures their increased uptake, achieving high systemic levels in non-metabolized forms. Nano-capsules confer a gradual release to these compounds, as well as longer half-lives and cell and whole organism permanence, reinforcing their effectiveness, as demonstrated in pre-clinical trials, enabling their application as an adjuvant therapy against cardiovascular diseases. Polyphenol entrapment in nanoparticles should be encouraged in nutraceutical manufacturing for the fortification of foods and beverages. This study discusses pre-clinical trials evaluating how nano-encapsulate polyphenols following oral administration can aid in cardiovascular performance.

scholarly journals Health Benefits and Molecular Mechanisms of Resveratrol: A Narrative Review

Foods ◽  
2020 ◽  
Vol 9 (3) ◽  
pp. 340 ◽  
Author(s):  
Xiao Meng ◽  
Jing Zhou ◽  
Cai-Ning Zhao ◽  
Ren-You Gan ◽  
Hua-Bin Li
Keyword(s):  
Clinical Trials ◽  
Cardiovascular Diseases ◽  
Chronic Diseases ◽  
Liver Diseases ◽  
Molecular Mechanisms ◽  
Health Benefits ◽  
Experimental Studies ◽  
Bioactive Compound ◽  
Protective Effects ◽  
Epidemiological Surveys

Resveratrol is a bioactive compound in many foods. Since its anticancer activity was reported in 1997, its health benefits have been intensively investigated. Resveratrol has antioxidant, anti-inflammatory, immunomodulatory, glucose and lipid regulatory, neuroprotective, and cardiovascular protective effects, therefore, can protect against diverse chronic diseases, such as cardiovascular diseases (CVDs), cancer, liver diseases, obesity, diabetes, Alzheimer’s disease, and Parkinson’s disease. This review summarizes the main findings of resveratrol-related health benefits in recent epidemiological surveys, experimental studies, and clinical trials, highlighting its related molecular mechanisms. Resveratrol, therefore, has been regarded as a potent candidate for the development of nutraceuticals and pharmaceuticals to prevent and treat certain chronic diseases.

Digital risk analysis of cardiovascular diseases: new opportunities for the patients

2008 ◽  
Vol 149 (15) ◽  
pp. 677-684 ◽  
Author(s):  
Csaba Arnold ◽  
Zoltán Englert ◽  
Csaba Szabadhegyi ◽  
Csaba Farsang
Keyword(s):  
Risk Factors ◽  
Cardiovascular Diseases ◽  
Risk Analysis ◽  
Effective Treatment ◽  
Medical History ◽  
Vascular Diseases ◽  
Coronary Risk ◽  
Risk Status ◽  
Long Period ◽  
Graphic Presentation

Authors constructed a software helping the prevention programme of coronary and vascular diseases as the classical risk factors are used for graphic presentation of coronary risk as compared to “normal” risk. By repeated estimation alterations in coronary risk status can be compared to previous ones and thereby help evaluating the changes. This programme is highlighted by the presentation of changes in coronary risk of a patient during a 4-year-long period of her medical history. It is also shown how graphic presentation of risk can support the more effective treatment and patient care.

scholarly journals Adjuvant Therapy for High Risk Localized Kidney Cancer: Emerging Evidence and Future Clinical Trials

2018 ◽  
Vol 199 (1) ◽  
pp. 43-52 ◽  
Author(s):  
Andrew T. Lenis ◽  
Nicholas M. Donin ◽  
David C. Johnson ◽  
Izak Faiena ◽  
Amirali Salmasi ◽  
...  
Keyword(s):  
Clinical Trials ◽  
High Risk ◽  
Adjuvant Therapy ◽  
Kidney Cancer

The Effect of Green Coffee Consumption on High Blood Pressure

2021 ◽  
Author(s):  
Mahdieh Hosseinzadeh ◽  
Fatemeh Pakravanfar ◽  
Elham Hosseinzadeh ◽  
Maryam Khosravi
Keyword(s):  
Blood Pressure ◽  
Clinical Trials ◽  
High Blood Pressure ◽  
Coffee Consumption ◽  
Vascular Diseases ◽  
Publication Date ◽  
Green Coffee ◽  
Chlorogenic Acids ◽  
Coffee Intake ◽  
Randomized Controlled Clinical Trials

Background: Hypertension is a major risk factor for the development of coronary, cerebrovascular, and peripheral vascular diseases, which lead to myocardial infarction, stroke, and vascular death. Green coffee extract is particularly producer a great deal of chlorogenic acids (CGA) that may reduce the risk of high blood pressure. Therefore, the target of the study was to summarize the available publications on the effect of green coffee consumption on high blood pressure. Methods: The systematic review was done with a search in PubMed-Medline and Scopus. The search strategy included keywords related to blood pressure and green coffee. Inclusion criteria were randomized controlled clinical trials conducted on people aged between 18 and 70 years. The publication date of articles  was from 2004 to 2018. Exclusion criteria were articles not published in English. Results: We discussed five articles that included  our criteria. Green coffee had moderate effects on high blood pressure.  It sounds that the effect of green coffee on reducing blood pressure is because of its phenolic compounds, as well as caffeine and chlorogenic acids, coffee’s roasting status, participants’ ethnicity, and even gender. Conclusion: Green coffee intake for a long time might moderately decrease blood pressure. However, there is still a need for further clinical trials.

scholarly journals Population-Based Linkage of Big Data in Dental Research

2018 ◽  
Vol 15 (11) ◽  
pp. 2357 ◽  
Author(s):  
Tim Joda ◽  
Tuomas Waltimo ◽  
Christiane Pauli-Magnus ◽  
Nicole Probst-Hensch ◽  
Nicola Zitzmann
Keyword(s):  
Clinical Trials ◽  
Big Data ◽  
Healthcare Services ◽  
Population Based ◽  
Services Research ◽  
Research Education ◽  
Data Anonymization ◽  
Dental Research ◽  
Epidemiological Surveys ◽  
Patient Consent

Population-based linkage of patient-level information opens new strategies for dental research to identify unknown correlations of diseases, prognostic factors, novel treatment concepts and evaluate healthcare systems. As clinical trials have become more complex and inefficient, register-based controlled (clinical) trials (RC(C)T) are a promising approach in dental research. RC(C)Ts provide comprehensive information on hard-to-reach populations, allow observations with minimal loss to follow-up, but require large sample sizes with generating high level of external validity. Collecting data is only valuable if this is done systematically according to harmonized and inter-linkable standards involving a universally accepted general patient consent. Secure data anonymization is crucial, but potential re-identification of individuals poses several challenges. Population-based linkage of big data is a game changer for epidemiological surveys in Public Health and will play a predominant role in future dental research by influencing healthcare services, research, education, biotechnology, insurance, social policy and governmental affairs.

scholarly journals Is there a role for adjuvant therapy after surgery in “high risk for recurrence” kidney cancer? An update on current concepts

2018 ◽  
Vol 25 (5) ◽  
Author(s):  
T. Sharma ◽  
C. Tajzler ◽  
A. Kapoor
Keyword(s):  
Clinical Trials ◽  
Targeted Therapy ◽  
High Risk ◽  
Adjuvant Therapy ◽  
Patient Population ◽  
Treatment Options ◽  
Significant Proportion ◽  
High Risk Patient ◽  
Disease Free Survival ◽  
Cochrane Reviews

BackgroundAlthough surgical resection remains the standard of care for localized kidney cancers, a significant proportion of patients experience systemic recurrence after surgery and hence might benefit from effective adjuvant therapy. So far, several treatment options have been evaluated in adjuvant clinical trials, but only a few have provided promising results. Nevertheless, with the recent development of targeted therapy and immunomodulatory therapy, a series of clinical trials are in progress to evaluate the potential of those novel agents in the adjuvant setting. In this paper, we provide a narrative review of the progress in this field, and we summarize the results from recent adjuvant trials that have been completed.MethodsA literature search was conducted. The primary search strategy at the medline, Cochrane reviews, and http://ClinicalTrials.gov/ databases included the keywords “adjuvant therapy,” “renal cell carcinoma,” and “targeted therapy or/and immunotherapy.”ConclusionsData from the s-trac study indicated that, in the “highest risk for recurrence” patient population, disease-free survival was increased with the use of adjuvant sunitinib compared with placebo. The assure trial showed no benefit for adjuvant sunitinib or sorafenib in the “intermediate- to high-risk” patient population. The ariser (adjuvant girentuximab) and protect (adjuvant pazopanib) trials indicated no survival benefit, but subgroup analyses in both trials recommended further investigation. The inconsistency in some of the current results can be attributed to a variety of factors pertaining to the lack of standardization across the trials. Nevertheless, patients in the “high risk of recurrence” category after surgery for their disease would benefit from a discussion about the potential benefits of adjuvant treatment and enrolment in ongoing adjuvant trials.

Adjuvant Therapy for Breast Cancer: Recommendations for Management Based on Consensus Review and Recent Clinical Trials

2002 ◽  
Vol 7 (3) ◽  
pp. 246-250 ◽  
Author(s):  
Betty A. Mincey ◽  
Frances M. Palmieri ◽  
Edith A. Perez
Keyword(s):  
Breast Cancer ◽  
Clinical Trials ◽  
Adjuvant Therapy

scholarly journals Antiartherosclerotic Effects of Plant Flavonoids

2014 ◽  
Vol 2014 ◽  
pp. 1-11 ◽  
Author(s):  
Shamala Salvamani ◽  
Baskaran Gunasekaran ◽  
Noor Azmi Shaharuddin ◽  
Siti Aqlima Ahmad ◽  
Mohd Yunus Shukor
Keyword(s):  
Cardiovascular Diseases ◽  
Side Effects ◽  
Animal Models ◽  
Vascular Diseases ◽  
Lipid Lowering ◽  
Peripheral Vascular ◽  
Heart Attacks ◽  
Synthetic Drug

Atherosclerosis is the process of hardening and narrowing the arteries. Atherosclerosis is generally associated with cardiovascular diseases such as strokes, heart attacks, and peripheral vascular diseases. Since the usage of the synthetic drug, statins, leads to various side effects, the plants flavonoids with antiartherosclerotic activity gained much attention and were proven to reduce the risk of atherosclerosisin vitroandin vivobased on different animal models. The flavonoids compounds also exhibit lipid lowering effects and anti-inflammatory and antiatherogenic properties. The future development of flavonoids-based drugs is believed to provide significant effects on atherosclerosis and its related diseases. This paper discusses the antiatherosclerotic effects of selected plant flavonoids such as quercetin, kaempferol, myricetin, rutin, naringenin, catechin, fisetin, and gossypetin.

Sign in / Sign up

Export Citation Format

Share Document